Session at ASH 2017, Photo courtesy of ASH

The 59th ASH Annual Meeting & Exposition took place December 9-12, 2017, in Atlanta, Georgia.

Update of gene therapy in hemophilia A

Print Friendly, PDF & Email


K. John Pasi, MBChB, PhD
© Todd Buchanan 2017
Updated trial results have shown that gene therapy can increase factor VIII (FVIII) levels and reduce the need for FVIII infusions in patients with severe hemophilia A. Most patients who received the gene therapy, valoctocogene roxaparvovec (VR, formerly BMN 270), were able to achieve normal... [Read Article]
Print Friendly, PDF & Email

Combo produces responses in R/R Ph+ ALL

Print Friendly, PDF & Email


Attendees at ASH 2017
Photo courtesy of ASH
© Todd Buchanan 2017
A 2-drug combination has produced a high response rate in a small trial of patients with relapsed/refractory (R/R), Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The combination, inotuzumab ozogamicin and bosutinib, produced an overall response rate of 81% in this ongoing,... [Read Article]
Print Friendly, PDF & Email

Caplacizumab improves outcomes in aTTP

Print Friendly, PDF & Email


Marie Scully, MD
Caplacizumab can improve outcomes in patients with acquired thrombotic thrombocytopenic purpura (aTTP), according to research presented at the 2017 ASH Annual Meeting. In the phase 3 HERCULES trial, researchers compared caplacizumab, an anti-von Willebrand factor nanobody, plus standard care (plasma exchange and immunosuppression) to placebo plus standard care in patients... [Read Article]
Print Friendly, PDF & Email

Combo shows promise for elderly/unfit ALL patients

Print Friendly, PDF & Email


Attendees at ASH 2017
Photo courtesy of ASH
© Todd Buchanan 2017
Results of a phase 2 trial suggest treatment with ponatinib and steroids is feasible for patients with acute lymphoblastic leukemia (ALL) who are elderly and/or unfit for intensive chemotherapy and stem cell transplant. More than 90% of patients who received this... [Read Article]
Print Friendly, PDF & Email

DLBCL survivors at greater risk of autoimmune, infectious diseases

Print Friendly, PDF & Email


Poster session at ASH 2017
Photo courtesy of ASH
© Todd Buchanan 2017
A population-based study indicates that, compared to other cancer survivors, patients who survive diffuse large B-cell lymphoma (DLBCL) have an increased risk of autoimmune and infectious diseases. For example, investigators found the risk of being diagnosed with impaired humoral immunity was... [Read Article]
Print Friendly, PDF & Email

Ixazomib/lenalidomide maintenance promising after ASCT in MM

Print Friendly, PDF & Email


Attendees at ASH 2017
Photo courtesy of ASH
© Todd Buchanan 2017
Adding ixazomib to lenalidomide as maintenance therapy for newly diagnosed multiple myeloma (MM) patients after upfront autologous stem cell transplant (ASCT) appears promising, according to an update of a phase 2 study. The oral doublet produced an overall response rate of... [Read Article]
Print Friendly, PDF & Email

Study highlights need for induction strategy in elderly, frail MM patients

Print Friendly, PDF & Email


Sign at the 2017
ASH Annual Meeting
Initial results of the phase 2 HOVON-126 trial in newly diagnosed multiple myeloma (MM) patients have highlighted the need for an induction strategy in elderly and frail patients. The trial showed high overall response rates (ORRs) after induction with ixazomib, thalidomide, and low-dose dexamethasone. However, 62%... [Read Article]
Print Friendly, PDF & Email

Team develops new scoring systems for PMF

Print Friendly, PDF & Email


ASH 2017 attendees
Photo courtesy of ASH
Two novel prognostic scoring systems can help clinicians decide how to treat certain patients with primary myelofibrosis (PMF), according to a new study. The scoring systems, which build upon the International Prognostic Scoring System (IPSS), were developed for use in PMF patients age 70 and younger... [Read Article]
Print Friendly, PDF & Email

bb2121 induces durable, deepening responses in MM patients

Print Friendly, PDF & Email


James N. Kochenderfer, MD
Photo courtesy of ASH
© Phil McCarten 2017
Updated results from a phase 1 trial have shown that bb2121, a chimeric antigen receptor (CAR) T-cell product, can induce durable, deepening responses in patients with relapsed/refractory multiple myeloma (MM). Responses continue to improve from very good partial responses to... [Read Article]
Print Friendly, PDF & Email

Chemo-free combo should be option for rel/ref CLL, doc says

Print Friendly, PDF & Email


John F. Seymour, MBBS, PhD
The combination of venetoclax and rituximab (VR) should be a standard treatment option for adults with relapsed/refractory chronic lymphocytic leukemia (CLL), according to a speaker at the 2017 ASH Annual Meeting. Data from the phase 3 MURANO study showed that patients with relapsed/refractory CLL who received VR had... [Read Article]
Print Friendly, PDF & Email

Risk stratification may be possible with JCAR017

Print Friendly, PDF & Email


Attendees at ASH 2017
Photo courtesy of ASH
© Scott Morgan 2017
Data suggest a therapeutic window may exist for CAR T-cell expansion with JCAR017, according to a preliminary model. In a core set of 67 patients with diffuse large B-cell lymphoma (DLBCL) who had received JCAR017 in the TRANSCEND NHL 001 trial, investigators... [Read Article]
Print Friendly, PDF & Email

Allo-HSCT leads to long-term survival in MF

Print Friendly, PDF & Email


Attendees at ASH 2017
Photo courtesy of ASH
© Todd Buchanan 2017
One of the largest single-center studies of fludarabine/melphalan-based allogeneic hematopoietic stem cell transplant (allo-HSCT) for patients with myelofibrosis (MF) shows excellent overall survival (OS) with a low risk of relapse, according to investigators. Allo-HSCT is the only potential curative treatment modality... [Read Article]
Print Friendly, PDF & Email

Edoxaban noninferior to dalteparin for VTE in cancer

Print Friendly, PDF & Email


Gary E. Raskob, PhD
Edoxaban is noninferior to dalteparin for the treatment of cancer-associated venous thromboembolism (VTE), a phase 3 study suggests. In the Hokusai-VTE CANCER study, patients who received edoxaban had a lower rate of VTE recurrence but a higher rate of major bleeding than patients who received dalteparin. Rates of VTE... [Read Article]
Print Friendly, PDF & Email

Ruxolitinib improves survival for MF patients in CP-e

Print Friendly, PDF & Email


Sign at the 2017
ASH Annual Meeting
A new study suggests the JAK2 inhibitor ruxolitinib has the potential to significantly improve survival in patients who have chronic phase (CP) myelofibrosis (MF), with or without elevated blasts. In this retrospective study, researchers found evidence to suggest that MF patients in CP with elevated blasts... [Read Article]
Print Friendly, PDF & Email